secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2026-06-24T20:22:04+00:00
Accession:  0001628280-26-045194
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics stockholders elect directors, approve equity plan amendment including pre-funded warrants
--------------------------------------------------------------------------------

- Three Class III directors (Hirsch, Fawell, Koppikar) re-elected with 47.8M–46.5M votes for each.
- Non-binding advisory vote on executive compensation approved: 54.9M for, 1.07M against.
- Stockholders ratified KPMG as independent auditor for fiscal 2026 with 76.9M votes in favor.
- Amendment to 2020 Stock Plan approved: includes pre-funded warrants in Outstanding Shares definition for evergreen increase calculation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026045194/0001628280-26-045194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026045194/cccc-20260624.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-045194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer